AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Niagen Bioscience, Inc. Director's Dealing 2008

Oct 29, 2008

32418_dirs_2008-10-29_92abdc17-f56e-47c6-93d6-e1076e55949b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2008-10-20

Reporting Person: Jaksch Frank L Jr (Director, President and CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2008-10-20	Common Stock	G	6225155	—	Disposed	0	Direct
2008-10-20	Common Stock	G	6225155	—	Acquired	6225155	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1429000	Indirect

Footnotes

F1: The reporting person transferred these shares to Black Sheep, F.L.P., a family limited partnership of which the reporting person and his wife are the sole co-general partners and of which the reporting person, his wife and the 2008 Jaksch Family Trust UTD June 25, 2008, Frank L. Jaksch, Jr. and Tricia A. Jaksch Trustees are the sole limited partners.